Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247)

• Status: Completed
• Trial end date: 2006-03-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to demonstrate improvement in overall survival for the combination of whole brain radiation therapy (WBRT) plus temozolomide (TMZ) versus WBRT alone. Secondary objective is to demonstrate an improvement in the time to radiological CNS progression with the addition of TMZ to WBRT.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Dacarbazine; Temozolomide

Criteria

• Age greater than or equal to 18

• Histologically or cytologically confirmed non-small-cell lung cancer (NSCLC)

• At least one brain metastasis diagnosed within 30 days of randomization

• Brain metastases must not have been previously treated with WBRT or radiosurgery

• No more than 2 sites of extracranial metastases

• May have received prior radiation therapy to the primary tumor and/or systemic metastatic sites

• Meets protocol requirements for specified laboratory values.

• Written informed consent and cooperation of patient

• Appropriate use of effective contraception if of childbearing potential.

• Karnofsky Performance Status KPS greater than 70

• Score less than 2 on all criteria of the Comprehensive Neurological Outcome Scale (CNOS)